Business
Viridian Therapeutics Announces Presentations at the 49th Annual Meeting of the North American Neuro-Ophthalmology Society
- Data from ongoing Phase 1/2 trial of VRDN-001 to be presented during oral platform session - - Additional poster presentations to cover trial design,
About this update from Viridian Therapeutics, Inc.
[{"type":"text","content":"- Data from ongoing Phase 1/2 trial of VRDN-001 to be presented during oral platform session - - Additional poster presentations to cover trial design, early-stage clinical and mechanistic data on pipeline candidates in Company’s thyroid eye disease program - WALTHAM, Mass., March 07, 2023 (GLOBE NEWSWIRE) -- Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced that multiple abstracts on VRDN-001 and VRDN-002—the Company’s investigational therapies for the treatment of thyroid eye disease (TED)—will be presented at the 49th Annual Meeting of the North American Neuro-Ophthalmology Society (NANOS), to be held March 11 to 16, 2023, in Orlando, Florida. An oral presentation with data from the ongoing Phase 1/2 trial of VRDN-001, a full antagonist antibody to the insulin-like growth factor 1 receptor (IGF-1R), is scheduled for the morning of Tuesday, March 14, with four posters from Viridian’s TED program to be presented that evening. “We are pleased to present this encouraging data from our TED pipeline at this important annual gathering,” said Barrett Katz, M.D., M.B.A., Chief Medical Officer of Viridian. “Taken together, the clinical and mechanistic data we are sharing at NANOS strengthen our confidence not only in VRDN-001 as we work to enroll patients in our active THRIVE Phase 3 trial, but also in our ability to develop follow-on assets with the potential for subcutaneous self-administration to decrease treatment burdens on patients and their families living with TED.” Oral Presentation Title:VRDN-001, a Full Antagonist Antibody to IGF-1 Receptor for Thyroid Eye Disease (TED): Phase 1/2 Clinical Study in PatientsSession:Platform Session IIDate:Tuesday, March 14, 2023Time:7:30 a.m. to 7:45 a.m. EST Poster Presentations Title:VRDN-001, a Full Antagonist Antibody to IGF-1 Receptor in Development for Thyroid Eye Disease (TED): Interim Phase 1/2 Pharmacodynamic ResultsSession:Meet the Poster Author: Analytical StudiesPoster:#298Date & Time:Tuesday, March 14, 6:00 p.m. to 8:30 p.m. Title:THRIVE: A Phase 3 Trial of VRDN-001, a Full Antagonist Antibody to IGF-1 Receptor for Thyroid Eye Disease (TED)Session:Meet the Poster Author: Analytical StudiesPoster:#296Date & Time:Tuesday, March 14, 6:00 p.m. t...